Skip to main content
Clinical Trials/NCT06043349
NCT06043349
Active, not recruiting
Phase 4

Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination Compared to Topical 5% Minoxidil Monotherapy in Male Androgenetic Alopecia

Indonesia University1 site in 1 country36 target enrollmentJune 1, 2023

Overview

Phase
Phase 4
Intervention
Platelet-Rich Plasma and Topical 5% Minoxidil
Conditions
Androgenetic Alopecia
Sponsor
Indonesia University
Enrollment
36
Locations
1
Primary Endpoint
Hair Density
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this clinical trial is to learn about the effectiveness and safety of platelet-rich plasma (PRP) and topical 5% minoxidil combination therapy compared with topical 5% minoxidil monotherapy in male androgenetic alopecia.

The main questions it aims to answer are:

  • Is there a difference in average change of hair density between groups that were given a combination of PRP injection and topical minoxidil compared to topical minoxidil as monotherapy?
  • Is there a difference in average change of hair thickness between groups that were given a combination of PRP and topical minoxidil compared to topical minoxidil as monotherapy?
  • Are there any differences in side effects between groups that were given combination of PRP and topical minoxidil compared to topical minoxidil as monotherapy?

Detailed Description

The trial will be held for three months in Jakarta, Indonesia. Participants are required to undergo hair examinations every 4 weeks, for a total of 4 visits. Researchers will compare groups that were given a combination of PRP and topical minoxidil compared to topical minoxidil alone as a control group. Hair density, hair thickness, and overall side effects of treatment will be measured at each visit.

Registry
clinicaltrials.gov
Start Date
June 1, 2023
End Date
September 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Adhika Ayu Lestari

MD

Indonesia University

Eligibility Criteria

Inclusion Criteria

  • Men between 18 and 50 years old
  • Diagnosed with grade III-VI androgenetic alopecia based on Hamilton-Norwood scale
  • Willing to be the research subject and make regular follow-up visits.

Exclusion Criteria

  • Conditions of baldness other than androgenetic alopecia based on anamnesis and physical examination, namely telogen effluvium, alopecia areata, trichotillomania, syphilis secondary, systemic lupus erythematosus, alopecia due to chemotherapy, autoimmune, or malignancy.
  • Taking oral medications or vitamins that aim to increase the amount of hair in the last 1 month.
  • Using topical medication that aims to increase the amount of hair in the last 2 weeks.
  • Suffering from active bacterial, viral, or fungal infections of the scalp.
  • Underwent cosmetic procedures for androgenetic alopecia treatment (such as PRP injections, laser procedures, or microneedle) within the last 3 months prior to the study.
  • History of keloids.
  • History of blood clotting disorders.

Arms & Interventions

Intervention Group

The first group, called the intervention group, will receive a combination therapy of platelet-rich plasma injection (PRP) with topical 5% minoxidil for three months. PRP injection will be given every 4 weeks with a total of three injections. Respondents will be instructed to apply topical minoxidil twice daily for three months.

Intervention: Platelet-Rich Plasma and Topical 5% Minoxidil

Control Group

The second group (control group) will receive topical 5% minoxidil as standard therapy. Respondents will be instructed to apply topical minoxidil twice daily for three months.

Intervention: Topical 5% Minoxidil

Outcomes

Primary Outcomes

Hair Density

Time Frame: Three months

Change in average hair density will be reported in /cm2

Hair Thickness

Time Frame: Three months

Change in average hair thickness will be reported in milimeters

Secondary Outcomes

  • Subjective side effects(Three months)
  • Objective side effects(Three months)

Study Sites (1)

Loading locations...

Similar Trials